Press Center

h2o Therapeutics announced that it has received European Union Medical Device Regulation (EU MDR) Class IIa certification for Parky, a mobile app designed to monitor and manage Parkinson's Disease (PD) symptoms…

h2o Therapeutics announces collaboration with AmerisourceBergen to support the commercialization of Apple Watch-Based App Parky for Parkinson's Disease

ANKARA, Turkey, Nov. 20, 2022 (GLOBE NEWSWIRE) -- Digital health start-up H2o therapeutics received 510(k) marketing clearance from the U.S. Food and Drug Administration for its prescription mobile app Parky for monitoring Parkinson's Disease.…

h2o Therapeutics and Lovell Announce Partnership to Increase Access to Parky for VA, DoD h2o Therapeutics Teams Up with Lovell to Expand Parky Access Across Federal Healthcare Networks PENSACOLA ,…